Jump Trading’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jump Trading’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-37	Closed	-$388K	–	595
2015 Q4	$388K	Buy	+37	New	+$3.86K	0.01%	516
2015 Q3	–	Sell	-7,500	Closed	-$1.03M	–	501
2015 Q2	$1.03M	Buy	+7,500	New	+$929K	0.02%	283
2014 Q4	–	Sell	-2,900	Closed	-$209K	–	977
2014 Q3	$209K	Buy	+2,900	New	+$191K	0.01%	620

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jump Trading's BMRN Position: Q2 2019 in Review

Jump Trading sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 4,444 shares — an estimated $395K sold.

Jump Trading first reported a position in BMRN in Q3 2014 and held it in 4 quarters. The position peaked at $603K in Q2 2015. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Jump Trading reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Jump Trading sold 4,444 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $395K.
Jump Trading first reported a position in BioMarin Pharmaceuticals in Q3 2014 and held it in 4 quarters.
Jump Trading's BioMarin Pharmaceuticals position peaked at $603K in Q2 2015.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Jump Trading's 13F filing for Q2 2019, filed 14 Aug 2019.